Treating DHHC20-deficient NCI-H23 cells with the proteasome inhibitor MG132 or GSK3β inhibitor CHIR-9002 partially restored Myc protein levels, indicating the direct involvement of GSK3β-directed Myc proteasomal degradation in palmitoylation-dependent tumour growth [40]. Here, MYC is linked to neoplasm.